FGFR1 and head and neck squamous cell carcinoma: LY2874455 has been found to be useful in gastric and head and neck squamous cell carcinoma, and, notably, as a novel drug, it is resistant to most FGFR mutations resulting in drug resistance, including FGFR4 V550L and FGFR1–561 M, which partially compensates for the lack of futibatinib action, but its specific action needs to be further clarified.